-
Yunnan Baiyao and Huawei Partner on AI-Driven Drug Development
•
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a three-year partnership with Huawei Technologies Co., Ltd to explore the application of artificial intelligence (AI) in drug development. The collaboration will focus on macro and small molecule drug design, related diseases, and database development. Partnership…
-
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration (NMPA) has accepted a market filing from its non-wholly owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd for a combination therapy of fulvestrant and piroxetine in advanced breast cancer. This marks Xuanzhu Bio’s first filing for an…
-
Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme Corp. (MSD) has entered into a second licensing agreement, securing global development, manufacturing, and commercialization rights to an undisclosed investigational antibody drug conjugate (ADC) from Kelun’s pipeline. The deal includes an upfront payment of USD…
-
SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval
•
SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus monoclonal antibody (mAb), has received clinical trial approval from the National Medical Products Administration (NMPA). Development and ResearchF61 was co-developed by Yang Xiaoming’s team with CNBG and Liang Mifang’s team from the Chinese Center for…
-
Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development
•
China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell therapy, announced plans to raise USD 250 million through a secondary public offering of American Depositary Shares (ADSs). Each ADS represents two ordinary shares. The underwriters have a 30-day option to purchase an additional USD…
-
AbbVie’s Allergan Aesthetics CoolAdvantage Applicator Wins NMPA Approval
•
US-based AbbVie’s Allergan Aesthetics announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its CoolAdvantage applicator series, alongside its official market launch in China. Technology and FeaturesCoolSculpting utilizes a non-surgical process called cryolipolysis to target and reduce subcutaneous fat by cooling fat cells to…
-
Henlius Biotech’s Hanquyou Approved in Australia for HER2-Positive Cancers
•
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received marketing approval from Australia’s Therapeutic Goods Administration (TGA) for its Hanquyou (trastuzumab injection, EU trade name: Zercepac). The drug will be marketed under the trade names Tuzucip and Trastucip to treat HER2-positive early breast cancer, HER2-positive locally advanced breast…
-
Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct an open-label, multi-center Phase Ib/II clinical study of its SHR-1802 combined with SHR-1316 for advanced solid tumors. Drug Profiles Global PD-L1 MarketGlobal PD-L1 products include AstraZeneca’s Tecentriq…
